New Review Flunks Most States in Tobacco Prevention Funding

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 3
Volume 10
Issue 3

WASHINGTON-Only 17 states have committed substantial funds from the tobacco settlement to tobacco prevention and cessation programs, according to a new report released by the American Cancer Society, American Heart Association, Campaign for Tobacco-Free Kids, and American Lung Association.

WASHINGTON—Only 17 states have committed substantial funds from the tobacco settlement to tobacco prevention and cessation programs, according to a new report released by the American Cancer Society, American Heart Association, Campaign for Tobacco-Free Kids, and American Lung Association. Only 6 of the 17—Arizona, Indiana, Maine, Massachusetts, Minnesota, and Mississippi—have met or exceeded the minimum spending recommended by the CDC—20% to 25%.

Articles in this issue
First Racial-Ethnic Breast and Cervical Cancer Screening Data
Mitotic Activity Index IDs High-Risk Node-Negative Breast Cancer
Programs Help Women/Physicians Decide on Adjuvant Therapy for Breast Cancer
No Recurrence in 971 Breast Cancer Patients With Negative SLNs Sentinel Lymph Node Biopsy
Disclosure Issues in Cancer Gene Testing Worry Doctors
Functional Assessment of Geriatric Cancer Patients Needed
Mobile Mammography Programs Are Struggling to Survive
Ellence Research Fund Names 11 Grant Recipients
Hyperfractionated RT Ups Pharynx Cancer Survival
Internet Creates Virtual Radiology Department
Dioxin TCDD Finally Listed as ‘Known’ Human Carcinogen
Fish Oil Concentrate Increases Doxorubicin Efficacy in Animals
RT Plus Chemo Ups Bladder Cancer Survival
Ductal Lavage Provides Early Detection of Atypical Cells
Study Clarifies When to Start HIV Therapy
Recent Videos
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Patients with cancer are subjected to fewer radiotherapy-induced toxicities because of newer, more advanced technologies.
Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.
Receiving information regarding tumor-associated antigens or mutational statuses from biopsies may help treatment selection in GI malignancies.
An easy-to-access database allows one to see a patient’s cancer stage, prior treatment, and survival outcomes in a single place.
Related Content
Bladder cancer

Disitamab Vedotin/Toripalimab Combo Prolongs Survival in Frontline HER2+ Urothelial Cancer

Tim Cortese
October 19th 2025
Article

Disitamab vedotin plus toripalimab achieved a median 13.1-month PFS and median 31.5-month OS in patients with HER2-expressing advanced urothelial carcinoma.

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Exploring the ESMO 2025 Presentations That May Shift GU Oncology

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
October 16th 2025
Podcast

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Data from the ROSELLA trial show a consistent benefit with relacorilant plus nab-paclitaxel across PROC subgroups.

Relacorilant Regimen Improves PFS in Platinum-Resistant Ovarian Cancer

Ashling Wahner
October 19th 2025
Article

Data from the ROSELLA trial show a consistent benefit with relacorilant plus nab-paclitaxel across PROC subgroups.

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

Charting the Evolution of TKIs and Finding the Next Breakthrough in CML

Jorge E. Cortes, MD
October 13th 2025
Podcast

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

T-DXd showed a consistent duration of response advantage vs THP regardless of prior treatment and mutational status among HER2+ breast cancer subgroups.

Subgroup Analysis Yields Clinically Meaningful Responses With T-DXd in HER2+ Breast Cancer

Ariana Pelosci
October 19th 2025
Article

T-DXd showed a consistent duration of response advantage vs THP regardless of prior treatment and mutational status among HER2+ breast cancer subgroups.

Data from the INTERCEPT study support ctDNA clearance as a useful end point for potential benefit in studies assessing novel therapeutics.

Adjuvant Therapy Confers Postoperative ctDNA Clearance, DFS Benefit in CRC

Russ Conroy
October 19th 2025
Article

Data from the INTERCEPT study support ctDNA clearance as a useful end point for potential benefit in studies assessing novel therapeutics.